Chu Grenoble Alpes
Grenoble, 38043, France
NCT Number: NCT04682678
Our project is based on the fundamental hypothesis that epidural spinal cord stimulation (SCS) improves Freezing of gait (FOG) in patients with Parkinson's disease. In eight patients implantation of electrodes for SCS at the epidural thoracic level will be performed under general anaesthesia.
Evaluation of gait and motor symptoms will be performed with and without stimulation, after a 3-month period for each of the stimulation conditions.This is a pilot, single centre, prospective, randomized, double blinded, cross-over study.
Looking for future studies?
Notify Me50 year–85 year
All sexes
Interventional
Not applicable
Grenoble, 38043, France
Patients will be selected in the Movement Disorders Unit, Department of Neurology, University Hospital Grenoble. A preoperative assessment with gait assessment, clinical evaluation and Non-Motor Symptoms assessment will be realized. The implantation of electrodes for SCS at the epidural thoracic level connected to a neurostimulator at the abdominal level will be performed under general anaesthesia. During the first postoperative month, the optimization of SCS parameters will be performed by an experienced movement disorders neurologist.After the first post-operative month the patient will be randomized to the STIM ON condition (stimulation on, with the most effective parameters) or STIM OFF (without stimulation). The randomization will be performed in a double blinded fashion, by a neurologist working in open and not participating in the evaluations. After 3 months, the patient will be evaluated in a double blind condition, and the stimulation condition will be crossed for another period of 3 months. At the end of this second 3-month period, the patient will be again double-blind assessed. After this evaluation, the patient will enter the open phase of the study for a period of 6 months. For this last phase of the study, under STIM ON condition, an optimization of the stimulation settings will be realized, if necessary. At the end of this 6-month period of stimulation, the patient will be evaluated one last time. At all visits, clinical and gait evaluations will be carried out under chronic dopaminergic treatment. No change in antiparkinsonian treatment will be allowed during the entire study. Gait and clinical assessment will be performed at baseline and at the end of each double blinded phase and at 1-year follow-up. For the double-blind study the patient, the neurologist who performs the clinical evaluation and the expert who performs the gait test and analysis will be blind to the stimulation condition.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The implantation of electrodes for SCS at the epidural thoracic level connected to a neurostimulator at the abdominal level will be performed under general anaesthesia (hospitalization for 3 days in the Neurosurgery Department, CHUGA) in a maximum delay of 1 month following the preoperative assessment. During the first postoperative month, the optimization of SCS parameters will be performed by an experienced movement disorders neurologist.
Time frame: Month 6
gait testing
Time frame: Month 12
New FOG-questionnaire (NFOG-Q)
Time frame: Month 12
patient diary
Time frame: Month 12
New Freezing Of Gait-questionnaire (NFOG-Q)
Time frame: Month 12
Parkinsons disease questionnaire (PDQ39)
Time frame: Month 12
New FOG-questionnaire (NFOG-Q)
Time frame: Month 12
SCales for Outcomes in PArkinson's disease - Autonomic Dysfunction (SCOPA-AUT)
Time frame: Month 12
timed up and go test
University Hospital, Grenoble
Other
Spinal Cord Stimulation for Gait Disorders in Parkinson's Disease: a Pilot Study
Acronym: SCM-PARK
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05510739
Basal Ganglia Diseases, Behavior
Stockholm, Sweden
View Trial DetailsNCT05938673
Basal Ganglia Diseases, Brain Diseases
São Paulo, Brazil
View Trial DetailsNCT05110053
Basal Ganglia Diseases, Brain Diseases
Aarhus, Denmark
View Trial DetailsNCT03213873
Basal Ganglia Diseases, Behavior
Huddinge, Sweden
View Trial Details